Source: Aids research and therapy. Unidade: FM
Subjects: HIV, IMUNOGENICIDADE DA VACINA, CÉLULAS DENDRÍTICAS, SÍNDROME DE IMUNODEFICIÊNCIA ADQUIRIDA
ABNT
BAPTISTA, Marcella Vassao de Almeida et al. Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial. Aids research and therapy, v. 19, n. 1, 2022Tradução . . Disponível em: https://doi.org/10.1186/s12981-021-00426-z. Acesso em: 17 ago. 2024.APA
Baptista, M. V. de A., Silva, L. T. da, Samer, S., Oshiro, T. M., Shytaj, I. L., Giron, L. B., et al. (2022). Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial. Aids research and therapy, 19( 1). doi:10.1186/s12981-021-00426-zNLM
Baptista MV de A, Silva LT da, Samer S, Oshiro TM, Shytaj IL, Giron LB, Pena NM, Cruz N, Cunha Neto E, Duarte AJ da S. Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial [Internet]. Aids research and therapy. 2022 ; 19( 1):[citado 2024 ago. 17 ] Available from: https://doi.org/10.1186/s12981-021-00426-zVancouver
Baptista MV de A, Silva LT da, Samer S, Oshiro TM, Shytaj IL, Giron LB, Pena NM, Cruz N, Cunha Neto E, Duarte AJ da S. Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial [Internet]. Aids research and therapy. 2022 ; 19( 1):[citado 2024 ago. 17 ] Available from: https://doi.org/10.1186/s12981-021-00426-z